Literature DB >> 21656827

CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies.

Fang Wang1, Yan-Feng Zou, Xiao-Liang Feng, Hong Su, Fen Huang.   

Abstract

BACKGROUND: The results of recent published studies focusing on CYP17 polymorphisms in prostate cancer (PCa) susceptibility are often conflicting. We performed a meta-analysis based on 38 independent studies to evaluate the association.
METHODS: Data were collected from the following electronic databases: PubMed, Excerpta Medica Database, and Chinese Biomedical Literature Database, with the last report up to September 2010. Meta-analysis was conducted in a fixed/random effect model.
RESULTS: Thirty-eight independent studies including 34,782 cases and 38,626 controls on the association of CYP17 gene polymorphisms with PCa risk in different ethnic groups were identified. The meta-analysis was performed for five polymorphisms: rs743572 (A1/A2, 38 studies), rs6162 (C/T, 3 studies), rs619824 (C/A, 4 studies), rs2486758 (T/C, 4 studies), and rs10883782 (A/G, 4 studies). When all groups were pooled, we did not detect the association of rs743572 polymorphism with PCa risk. In the subgroup analysis, a significant association of rs743572 polymorphism and PCa was found in Black population (A2/A2 vs. A1/A1 + A2/A1: OR = 1.70, 95% CI = 1.08-2.69, P = 0.02), but not in Caucasian or Asian population. For other polymorphisms, we found that rs619824 polymorphism was associated with a significant decreased risk of PCa (A vs. C: OR = 0.95, 95% CI = 0.92-0.99, P = 0.01), and rs2486758 polymorphism was associated with a significant increased risk of PCa (C vs. T: OR = 1.07, 95% CI = 1.03-1.12, P = 0.002).
CONCLUSION: This meta-analysis suggests that rs743572 polymorphism is associated with PCa risk in Black population, but not in Caucasian or Asian population. Moreover, our study suggests that rs619824 and rs2486758 polymorphisms are associated with PCa risk.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656827     DOI: 10.1002/pros.21332

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  17 in total

Review 1.  Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Authors:  S Salvi; V Conteduca; G Gurioli; D Calistri; V Casadio; U De Giorgi
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

2.  CYP17 polymorphism (rs743572) is associated with increased risk of gallbladder cancer in tobacco users.

Authors:  Rajani Rai; Kiran L Sharma; Sanjeev Misra; Ashok Kumar; Balraj Mittal
Journal:  Tumour Biol       Date:  2014-04-01

3.  Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population.

Authors:  Monika Kmetová Sivoňová; Dušan Dobrota; Róbert Dušenka; Iveta Waczulíková; Peter Slezák; Tatiana Matáková; Silvia Mahmoodová; Dušan Mištuna; Ján Kliment
Journal:  Mol Biol Rep       Date:  2012-04-22       Impact factor: 2.316

4.  Estrogen receptor alpha gene polymorphisms and risk of prostate cancer: a meta-analysis involving 18 studies.

Authors:  Zhenwei Gu; Gang Wang; Weiguo Chen
Journal:  Tumour Biol       Date:  2014-03-01

5.  Male pattern baldness in relation to prostate cancer risks: an analysis in the VITamins and lifestyle (VITAL) cohort study.

Authors:  Cindy Ke Zhou; Alyson J Littman; Paul H Levine; Heather J Hoffman; Sean D Cleary; Emily White; Michael B Cook
Journal:  Prostate       Date:  2014-12-09       Impact factor: 4.104

6.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

7.  CYP17A1 T-34C polymorphism is not associated with endometrial cancer risk.

Authors:  Xueying Yang; Aihua Feng; Fengying Liu; Qun Li; Jing Zhang; Chuanhua Yang; Yujun An
Journal:  Tumour Biol       Date:  2013-04-23

8.  Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.

Authors:  Emanuela Taioli; Vestra Sears; Alexis Watson; Rafael E Flores-Obando; Maria D Jackson; Flora A Ukoli; Ilce M de Syllos Cólus; Pedro Fernandez; Norma McFarlane-Anderson; Elaine A Ostrander; Iara S Rodrigues; Janet L Stanford; Jack A Taylor; Marshall Tulloch-Reid; Camille C R Ragin
Journal:  Prostate       Date:  2012-11-05       Impact factor: 4.104

9.  Relationship between male pattern baldness and the risk of aggressive prostate cancer: an analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Cindy Ke Zhou; Ruth M Pfeiffer; Sean D Cleary; Heather J Hoffman; Paul H Levine; Lisa W Chu; Ann W Hsing; Michael B Cook
Journal:  J Clin Oncol       Date:  2014-09-15       Impact factor: 44.544

10.  Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Weronica E Ek; Katarina Lagergren; Michael Cook; Anna H Wu; Christian C Abnet; David Levine; Wong-Ho Chow; Leslie Bernstein; Harvey A Risch; Nicholas J Shaheen; Nigel C Bird; Douglas A Corley; Laura J Hardie; Rebecca C Fitzgerald; Marilie D Gammon; Yvonne Romero; Geoffrey Liu; Weimin Ye; Thomas L Vaughan; Stuart MacGregor; David C Whiteman; Lars Westberg; Jesper Lagergren
Journal:  Int J Cancer       Date:  2015-10-05       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.